On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in the U.S. and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine.

Novavax had previously reported positive interim efficacy results of NVX-CoV2373, its recombinant protein-based vaccine candidate, in an ongoing Phase 3 clinical trial taking place in the United Kingdom.